Fazpilodemab

DB18924InvestigationalProtein Based Therapies

Fazpilodemab is under investigation in clinical trial NCT04171765 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-alcoholic Steatohepatitis).

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 1 and Beta-klotho
Curator reviewed
Also known as: Anti-fgfr1/klb mab · Bfkb-8488a (bispecific antibody designed to mimic the metabolic hormone fgf21). · immunoglobulin G1-kappa, anti-[Homo sapiens KLB (klotho beta, b-Klotho)] and anti-[Homo sapiens FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2)], monoclonal antibody, bispecific; gamma1 heavy chain anti-KLB (1-450) [VH (Homo sapiens IGHV3-66*01 ( · mmunoglobulin G1 [369-serine,371-alanine,410-valine], anti-(human β-Klotho protein) (human monoclonal HKLB4206 γ1-chain), disulfide with monoclonal HKLB4206 κ-chain, (229→225'),(232→228')-bis(disulfide) with immunoglobulin G1 [365-tryptophan] ant
Code names: BFKB-8488A · RG-7992 · RO-7040551

Resolves to

Compound

UNIIVVE4UQ5M6PCAS2517935-02-1

Targets

P11362FGFR1Q86Z14KLB

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fazpilodemab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account